MMP9 and cancer: For example, MMP9 neutralizing antibody (andecaliximab) and anti-PD1 (nivolumab) was combined to treat gastric and esophageal cancers in the phase II clinical trial NCT02864381 [60], suggesting the potential re-application of MMP inhibitors in cancer therapy.